KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

MEI Pharma Stock Dividends Overview

MEIP pays dividends yearly. Last paid amount was $1.75 at Dec 06, 2023. As of today, dividend yield (TTM) is 26.52%.

Dividend Yield Range

The Dividend Yield Range is the range of values in which a stock’s dividend yield has fluctuated within a specified period, often a year. It represents the variation between the highest and lowest dividend yields observed during that time frame.
AI Analysis of MEIP
Powered by GPT-4
New!
Dividend Analysis

Key Stats

Dividend Yield (TTM) 26.52%
Frequency Yearly
1Y Growth 0%
Payout Ratio 0
Amount Per Share $1.75
MEI Pharma has not yet announced its next dividend date. Last payment date was: Dec 06, 2023.

MEIP Dividend Payout History

To ensure a understanding of MEIP's dividend performance, consider examining the historical payout ratios and how they align with the company's earnings. Fluctuations in payout amounts may reflect changes in the company's dividend policy or earnings stability.


# Declaration Date Ex-Date Pay Date Amount Yield
1 Nov 06, 2023 Nov 16, 2023 Dec 06, 2023 $1.75 26.52%

Dividend Sustainability

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Sustainability score

Average (88.83%)

Growth potential

Decrease likely (30.00%)

MEIP Dividend Calculator

Dividend Calculator is designed to forecast the potential returns from MEIP dividends based on your individual investment size or the number of shares you own. Simply enter your total investment amount to see the cumulative dividend payment you could receive over a specified period.
Read how to invest in MEIP stock here.

Comparing MEIP to Sector and Country

MEIP pays a solid dividend yield of 26.52%, which is higher than the average of the bottom 25% of dividend payers in the US market (0.373%). MEIP’s dividend yield is higher than the average of the top 25% of dividend payers in the Healthcare sector in the US market (7.44%).

MEIP Stock Competitors

Symbol Company Name Market Cap Amount Per Share Dividend Yield (TTM) Payout Ratio (TTM)
MEI Pharma 20.655M $1.75 26.52% -

FAQ

What factors can affect the amount of MEIP's dividend payments?
The amount of MEIP's dividends can fluctuate based on several factors, including the company's financial performance, earnings, cash flow, capital requirements, and overall market conditions. Changes in MEIP sector's trends, interest rate shifts, and the company's operational adjustments can also influence dividend decisions.

Can dividends from MEIP stock be automatically reinvested?
If MEIP offers a Dividend Reinvestment Plan (DRIP), shareholders may have the option to automatically reinvest dividends to purchase additional shares. Please check with your brokerage for the availability and details of such a plan. Here's an easy guide on how to buy MEIP stock.

How often does MEIP pay dividend?
MEI Pharma (MEIP) pays dividends yearly. The most recent payout was on Dec 06, 2023.

How much does MEIP pays per share?
The last recorder (Nov 16, 2023) dividend per share was $1.75.

What is MEIP dividend growth rate?
Over the last year, MEI Pharma has witnessed growth rate of 0% . Looking back over the past 3 years, this growth rate has been 0%. Furthermore, examining the past 5 years, MEI Pharma has maintained an average Dividends Per Share Growth Rate of 0%.
Click to get the best stock tips daily for free!

About MEI Pharma

MEI Pharma MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cycl... MEIP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT